Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo targets genetic weakness in prostate cancer

NCT ID NCT04821622

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study measures how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
talazoparib (a PARP inhibitor) combined with enzalutamide (a hormone therapy)
What this could lead to
If successful, this combination could slow or stop cancer growth better than enzalutamide alone, offering a new treatment option for men with this specific genetic mutation.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet confirmed. The combination may cause more side effects, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

599 people

The number who actually took part.

Started

May 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male participants at least 18 years of age at screening (20 years for Japan, 19 years for Republic of Korea). 2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, small cell or signet cell features. If the participant does not have a prior histological diagnosis, a baseline de novo biopsy must be used to confirm the diagnosis and may also be used to support biomarker analysis. 3. Confirmation of DDR gene mutation status by prospective or historical analysis (with sponsor pre-approval) of blood (liquid biopsy) and/or de novo or archival tumor tissue using FoundationOne Liquid CDx or FoundationOne CDx. 4. Willing to provide tumor tissue when available (de novo or archived) for retrospective molecular profiling analysis, if not already provided as part of inclusion criterion 3. 5. Unless prohibited by local regulations or ethics committee decision, consent to a saliva sample collection for retrospective sequencing of the same DDR genes tested on tumor tissue and blood (liquid biopsy), or a subset thereof, and to serve as a germline control in identifying tumor mutations. 6. Ongoing ADT with a GnRH agonist or antagonist for participants who have not undergone bilateral orchiectomy must be initiated before randomization and must continue throughout the study. 7. Metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on CT or MRI scan (for soft tissue). Participants whose disease spread is limited to regional pelvic lymph nodes are not eligible. Note: a finding of superscan at baseline is exclusionary. 8. Prior treatment of mCSPC with docetaxel is not permitted. 9. Treatment with estrogens, cyproterone acetate, or first-generation anti-androgens is allowed until randomization. 10. Other prior therapy allowed for mCSPC; ≤3 months of ADT (chemical or surgical) with or without approved NHT in mCSPC (ie, abiraterone + prednisone, apalutamide, or enzalutamide), if required prior to randomization, with no radiographic evidence of disease progression or rising PSA levels prior to Day 1. 11. Participant may have received palliative radiation or surgery for symptomatic control secondary to prostate cancer, which should have been completed at least 2 weeks prior to randomization. NOTE: Radical prostatectomy or definitive radiotherapy to the primary tumor for metastatic castration-sensitive prostate cancer with curative intent is not permitted. 12. ECOG performance status 0 or 1. 13. Adequate organ function within 28 days before the first study treatment on Day 1, defined by the following: * ANC ≥1500/µL, platelets ≥100,000/µL, or hemoglobin ≥9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology laboratory tests at screening). * Total serum bilirubin \<1.5 × ULN (\<3 × ULN for participants with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation). * AST or ALT \<2.5 × ULN (\<5 × ULN if liver function abnormalities are due to hepatic metastasis). * Albumin \>2.8 g/dL. * eGFR ≥30 mL/min/1.73 m2 by the MDRD equation. 14. Sexually active participants that in the opinion of the investigator are capable of ejaculating, must agree to use a condom when having sex with a partner (female or male) from the time of the first dose of study treatment through 4 months after last dose of study treatment (or, if talazoparib/placebo has been stopped more than a month earlier than enzalutamide, through 3 months after last dose of enzalutamide). Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment (or, if talazoparib / placebo has been stopped more than a month earlier than enzalutamide, through 3 months after last dose of enzalutamide) when having sex. 15. Must agree not to donate sperm from the first dose of study treatment to 4 months after the last dose of study treatment (or, if talazoparib/placebo has been stopped more than a month earlier than enzalutamide, through 3 months after last dose of enzalutamide). 16. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures, including being able to manage electronic diaries. The PRO assessments are not required to be completed if a patient does not understand the language(s) available for a specific questionnaire and/or cannot complete the specific questionnaire independently. 17. Capable of giving signed informed consent. 18. For France only: Participants affiliated with the social security system or beneficiaries of an equivalent system. Exclusion Criteria: 1. Other acute or chronic medical (concurrent disease, infection, including chronic stable HIV, HBV, or HCV infection, or co-morbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that interferes with a participant's ability to participate in the study, may increase the risk of associated with study participation or study treatment administration, or may interfere with the interpretation of study results, and, in the investigator's judgment, make the participant inappropriate for entry into the study. HIV/HBV/HCV testing is not required unless mandated by local health authority. 2. History of seizure or any condition (as assessed by investigator) that may predispose to seizure (eg, prior cortical stroke, significant brain trauma), including any history of loss of consciousness or transient ischemic attack within 12 months of randomization. 3. Major surgery (as defined by the investigator) within 4 weeks before randomization. 4. Known or suspected brain metastasis or active leptomeningeal disease. 5. Symptomatic or impending spinal cord compression or cauda equina syndrome. 6. Any history of MDS, AML, or prior malignancy except for the following: * Carcinoma in situ or non-melanoma skin cancer. * A cancer diagnosed and treated ≥3 years before randomization with no subsequent evidence of recurrence. * American Joint Committee on Cancer Stage 0 or Stage 1 cancer \<3 years before randomization that has a remote probability of recurrence in the opinion of the investigator and the sponsor. 7. In the opinion of the investigator, any clinically significant gastrointestinal disorder affecting absorption. 8. Clinically significant cardiovascular disease, including any of the following: * Myocardial infarction or symptomatic cardiac ischemia within 6 months before randomization. * Congestive heart failure New York Heart Association class III or IV. * History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes) within 1 year before screening. * History of Mobitz II second degree or third-degree heart block unless a permanent pacemaker is in place. * Hypotension as indicated by systolic blood pressure \<86 mm Hg at screening. * Bradycardia as indicated by a heart rate of \<45 beats per minute on the screening electrocardiogram. * Uncontrolled hypertension as indicated by systolic blood pressure \>170 mm Hg or diastolic blood pressure \>105 mm Hg at screening. However, participants can be rescreened after adequate control of blood pressure is achieved. 9. Active COVID-19 infection detected by viral test or based on clinical diagnosis (as assessed by investigator). Asymptomatic participants with no active COVID-19 infection detected but positive antibody tests, indicating past infection are allowed. 10. Prior ADT in the adjuvant/neoadjuvant setting, where the completion of ADT was less than 12 months prior to randomization and the total duration of ADT exceeded 36 months. 11. Participant received treatment with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to randomization, intended for the treatment of prostate cancer. 12. Any previous treatment with DNA-damaging cytotoxic chemotherapy (ie, platinum based therapy) within 5 years prior to randomization, except for indications other than prostate cancer. 13. Prior treatment with a PARPi, or known or possible hypersensitivity to enzalutamide, any of enzalutamide capsule excipients or to any talazoparib/placebo capsule excipients. 14. Prior treatment in any setting with NHT, except as described in Inclusion Criterion #10. 15. Current use of potent P-gp inhibitors within 7 days prior to randomization. 16. Treatment with any investigational study intervention within 4 weeks before randomization. Exception: COVID-19 vaccines authorized under an emergency use authorization (or equivalent) can be administered without a washout period. 17. Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, QTcF interval \>470 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is \>470 msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants. 18. Investigator site staff or Sponsor employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. 19. For France only: Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric care, as well as adults subject to a legal protection measure (guardianship, curatorship, and safeguard of justice) covered by Articles 1121-6 to 1121-8 of the Public Health Code.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DDR-deficient metastatic castration-sensitive prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • 15 Eton Road

    Johannesburg, Gauteng, 2193, South Africa

  • ASST Cremona

    Cremona, CR, 26100, Italy

  • ASST Papa Giovanni XXIII

    Bergamo, 24127, Italy

  • ASST degli Spedali Civili de Brescia

    Brescia, 25123, Italy

  • AZ (Algemeen Ziekenhuis) Groeninge

    Kortrijk, 8500, Belgium

  • AZ (Algemeen Ziekenhuis) Maria Middelares

    Ghent, 9000, Belgium

  • AZ (Algemeen Ziekenhuis) Sint-Lucas

    Ghent, 9000, Belgium

  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment EOOD

    Sofia, Bulgaria

  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda EAD

    Sofia, 1407, Bulgaria

  • Adana City Training and Research Hospital

    Adana, 01415, Turkey (Türkiye)

  • AdventHealth Medical Group Hematology and Oncology

    Orlando, Florida, 32804, United States

  • Adventist Health Glendale

    Glendale, California, 91206, United States

  • Althaia, Xarxa Assistencial Universitària de Manresa

    Manresa, Barcelona, 08243, Spain

  • Ankara City Hospital

    Ankara, 06800, Turkey (Türkiye)

  • Ankara University Faculty of Medicine

    Ankara, 06620, Turkey (Türkiye)

  • Arizona Institute of Urology, PLLC

    Tucson, Arizona, 85704, United States

  • Artemis hospital

    Gurugram, Haryana, 122001, India

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asklepion Medical Center

    Khodosovka, Kyivska Oblast, 08173, Ukraine

  • Axis Heilsa S. de R.L. de C.V.

    Monterrey, Nuevo León, 64040, Mexico

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, 37134, Italy

  • Azienda Ospedaliera Universitaria San Luigi Gonzaga- Uinta di Oncologia Polmonare

    Orbassano, 10043, Italy

  • Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi

    Bologna, BO, 40138, Italy

  • Azienda Provinciale per i Servizi Sanitari, della Provincia Autonoma di Trento

    Trento, Trentino-Alto Adige, 38123, Italy

  • Azienda Unita Sanitaria Locale Toscana Sud-Est

    Arezzo, 52100, Italy

  • BHI of Omsk region "Clinical Oncological Dispensary"

    Omsk, 644013, Russia

  • Ballad Health Cancer Care - Kingsport

    Kingsport, Tennessee, 37660, United States

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211, United States

  • Bhaktivedanta Hospital and Research Institute

    Mumbai, Maharashtra, 401107, India

  • Branch of the Limited Liability Company "Hadassah Medical Ltd."

    Moscow, 121205, Russia

  • Bristol Regional Medical Center

    Bristol, Tennessee, 37620, United States

  • Budgetary Healthcare Institution of Vologda region "Vologda Regional Clinical Hospital"

    Vologda, 160002, Russia

  • Budgetary Healthcare Institution of Vologda region "Vologda Regional Clinical Hospital"

    Vologda, 160022, Russia

  • CHP Saint-Grégoire

    Saint-Grégoire, 35760, France

  • CHU Morvan de Brest

    Brest, Brittany Region, 29200, France

  • CHU de Liege

    Liège, 4000, Belgium

  • CHUM - Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X 0A9, Canada

  • CIUSSS- saguenay-Lac-Saint-Jean

    Chicoutimi, Quebec, G7H 5H6, Canada

  • COIBA

    Berazategui, Buenos Aires, B1884BBF, Argentina

  • Cabrini Hospital

    Malvern, Victoria, 3144, Australia

  • Cancer Care Wollongong Pty Limited

    Wollongong, New South Wales, 2500, Australia

  • Carolina Urologic Research Center, LLC

    Myrtle Beach, South Carolina, 29572, United States

  • Centre Hospitalier Universitaire d'Angers

    Angers, 49933, France

  • Centre Hospitalier de I'Universite de Montreal (CHUM)

    Montreal, Quebec, H2X 0A9, Canada

  • Centre Leon Berard

    Lyon, 69373, France

  • Centre integre universitaire de sante et de services sociaux Saguenay-Lac-Saint-Jean

    Chicoutimi, Quebec, G7H 7K9, Canada

  • Centre of Applied Urology Research, Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Centro Medico Privado CEMAIC

    Córdoba, X5008HHW, Argentina

  • Centro Medico San Roque

    San Miguel de Tucumán, Tucumán Province, T4000IAK, Argentina

  • Centro Oncologico Korben

    Caba, C1426AGE, Argentina

  • Centro de Investigacion Clinica de Oaxaca

    Oaxaca City, 68020, Mexico

  • Centro de Investigacion Pergamino SA - Clinica Pergamino SA

    Pergamino, Buenos Aires, B2700CPM, Argentina

  • Centro de Investigaciones Clínicas - Clínica Viedma

    Viedma, Río Negro Province, R8500ACE, Argentina

  • Centro di Riferimento Oncologico di Aviano (CRO) IRCCS

    Aviano, PN, 33081, Italy

  • Charite Universitaetsmedizin Berlin - Campus Mitte

    Berlin, 10117, Germany

  • Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, Gauteng, 2193, South Africa

  • Chiba cancer center

    Chiba, Chiba, 2608717, Japan

  • Chonnam National University Hwasun Hospital

    Hwasun-gun, Jeollanam-do, 58128, South Korea

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Clinical Research Institute Helsinki University Central Hospital Ltd

    Helsinki, 00280, Finland

  • Clinical Research Unit, University of Pretoria

    Pretoria, Gauteng, 0002, South Africa

  • Clinique Belharra

    Bayonne, 64100, France

  • Clinique La Croix du Sud - Ramsay Sante

    Quint-Fonsegrives, 31130, France

  • Clinique Victor Hugo Le Mans

    Le Mans, Pays de la Loire Region, 72000, France

  • Cliniques universitaires Saint-Luc

    Brussels, 1200, Belgium

  • Comm Noncommerc Entp Lviv Reg Council "Lviv Oncological Regional Therapeutical and Diagnostic Cntre

    Lviv, 79031, Ukraine

  • Communal Non-Profit Enterprise "Regional Center of Oncology"

    Kharkiv, 61070, Ukraine

  • Complejo Hospitalario de Navarra

    Pamplona, Navarre, 31008, Spain

  • Complex Oncology Center - Plovdiv EOOD

    Plovdiv, 4000, Bulgaria

  • Complex Oncology Center - Shumen EOOD

    Shumen, 9700, Bulgaria

  • Complex Oncology Center - Stara Zagora Ltd.

    Stara Zagora, 6003, Bulgaria

  • Complex Oncology Center- Plovdiv EOOD

    Plovdiv, 4000, Bulgaria

  • Comprehensive Urologic Care, SC

    Lake Barrington, Illinois, 60010, United States

  • David C. Pratt Cancer Center

    St Louis, Missouri, 63141, United States

  • Docrates Cancer Center

    Helsinki, 00180, Finland

  • Epworth Foundation Trading as Epworth HealthCare

    Richmond, Victoria, 3121, Australia

  • Epworth Freemasons-Epworth HealthCare

    East Melbourne, Victoria, 3002, Australia

  • Evimed Llc

    Chelyabinsk, 454048, Russia

  • Ewha Womans University Mokdong Hospital

    Seoul, 07985, South Korea

  • Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica

    Banská Bystrica, 975 17, Slovakia

  • Fakultni Nemocnice Motol a Homolka

    Prague, 150 00, Czechia

  • Fakultni nemocnice Bulovka

    Praha 8- Liben, 180 81, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, 100 34, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, 779 00, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava - Poruba, 708 52, Czechia

  • Federal State Budgetary Institution "Central Clinical Hospital with ambulance"

    Moscow, 121359, Russia

  • Federal State Budgetary Institution "Russian Research Center of Roentgenology and Radiology" of the

    Moscow, 117997, Russia

  • Fondazione Casa Sollievo della Sofferenza

    San Giovanni Rotondo, FG, 71013, Italy

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, 200032, China

  • Fundación Instituto Valenciano de Oncología

    Valencia, Valenciana, Comunitat, 46009, Spain

  • Gallipoli Medical Research Foundation, Greenslopes Private Hospital

    Brisbane, Queensland, 4120, Australia

  • Gangnam Severance Hospital, Yonsei University Health System

    Seoul, 06273, South Korea

  • Gold Coast University Hospital

    Southport, Queensland, 4215, Australia

  • Goztepe Prof. Dr. Suleyman Yalcin City Hospital

    Istanbul, 34722, Turkey (Türkiye)

  • Greater Glasgow Health Board J B Russell House, Gartnavel Royal Hospital

    Glasgow, Scotland, G12 0XH, United Kingdom

  • Gujarat Hospital - Gastro and Vascular Centre

    Surat, Gujarat, 395009, India

  • Gustave Roussy

    Villejuif, 94805, France

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Helsinki University Hospital

    Helsinki, 00029, Finland

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450003, China

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Henry Ford Medical Center - New Center One

    Detroit, Michigan, 48202, United States

  • Hirosaki University School of Medicine & Hospital

    Hirosaki, Aomori, 036-8563, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • Holston Valley Hospital and Medical Center

    Kingsport, Tennessee, 37660, United States

  • Hopital Bichat - Claude Bernard

    Paris, 75018, France

  • Hopital Bichat - Claude Bernard

    Paris, 75877, France

  • Hopital Henri Mondor

    Créteil, Île-de-France Region, 94010, France

  • Hopital Lyon Sud

    Pierre-Bénite, 69310, France

  • Hopital Prive le Bois

    Lille, 59000, France

  • Hopitaux Universitaires de Strasbourg - ICANS (Institut de Cancerologie Strasbourg Europe)

    Strasbourg, 67200, France

  • Hospital Clinico San Carlos

    Madrid, 28040, Spain

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

  • Hospital General Universitario de Elche

    Elche, Alicante, 03203, Spain

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona [barcelona], 08916, Spain

  • Hospital Politecnic Universitari La Fe

    Valencia, 46026, Spain

  • Hospital Universitari Sant Joan de Reus

    Reus, Tarragona, 43204, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, 64460, Mexico

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, 33011, Spain

  • Hospital Universitario Gregorio Marañón

    Madrid, 28009, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Galicia, 27003, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, Comunidad de, 28222, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, 14004, Spain

  • Hospital Universitario Virgen de la Macarena

    Seville, 41009, Spain

  • Houston Metro Urology

    Houston, Texas, 77027, United States

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah, 84112, United States

  • IRCCS Istituto Tumori "Giovanni Paolo II" di Bari

    Bari, 70124, Italy

  • Imperial College Healthcare NHS Trust

    London, W6 8RF, United Kingdom

  • Independent medical-diagnostic laboratory "Medisken" EOOD

    Plovdiv, 4000, Bulgaria

  • Indian Path Community Hospital

    Kingsport, Tennessee, 37660, United States

  • Indraprastha Apollo Hospital

    New Delhi, National Capital Territory of Delhi, 110076, India

  • Indraprastha Apollo Hospitals

    New Delhi, 600028, India

  • Inonu University, Faculty of Medicine

    Malatya, 44280, Turkey (Türkiye)

  • Institut Català d'Oncologia de l'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Institut Jean Godinot

    Reims, 51726, France

  • Institut Jules Bordet

    Anderlecht, 1070, Belgium

  • Institut Jules Bordet

    Brussels, 1000, Belgium

  • Institut de cancerologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

  • Institut fuer Diagnostische und Interventionelle Radiologie

    Göttingen, 37075, Germany

  • Instituto Médico Especializado Alexander Fleming

    CABA, C1426ANZ, Argentina

  • Instituto Veracruzano en Investigación Clínica S.C.

    Veracruz, 91851, Mexico

  • Investigational Drug Services, Advent Health Orlando

    Orlando, Florida, 32804, United States

  • Istanbul University, Cerrahpasa Faculty of Medicine

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli

    Naples, Naples, 80131, Italy

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST)

    Meldola, FC, 47014, Italy

  • Jahn Ferenc Del-pesti Korhaz es Rendelointezet

    Budapest, 1204, Hungary

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Jiangxi Provincial Cancer Hospital

    Nanchang, Jiangxi, 330029, China

  • Kagoshima University Hospital

    Kagoshima, 890-8520, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Keio university hospital

    Shinjuku-ku, Tokyo, 160-8582, Japan

  • Kelsey Research Foundation

    Houston, Texas, 77005, United States

  • Kelsey-Seybold Clinic

    Houston, Texas, 77014, United States

  • Kelsey-Seybold Clinic

    Houston, Texas, 77025, United States

  • Kelsey-Seybold Clinic

    Houston, Texas, 77055, United States

  • Keystone Urology Specialists

    Lancaster, Pennsylvania, 17604, United States

  • Kindai University Hospital

    Sakai, Osaka, 590-0197, Japan

  • Klinik fuer Nuklearmedizin

    Göttingen, 37075, Germany

  • Kuopio University Hospital

    Kuopio, 70210, Finland

  • Kyungpook National University Chilgok Hospital

    Daegu, 41404, South Korea

  • LLC "Medicina Severnoy Stolitsy"

    Saint Petersburg, 191025, Russia

  • LLC "Severo-Zapadny Medical Center"

    Saint Petersburg, 192007, Russia

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Preston, Lancashire, PR2 9HT, United Kingdom

  • Lanzhou university second hospital

    Lanzhou, Gansu, 730030, China

  • Limited Liability Company "4D Ultrasound Clinic" (LLC "4D Ultrasound Clinic")

    Pyatigorsk, Stavropol Kray, 357502, Russia

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City, 333, Taiwan

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • MD Anderson Cancer Center

    Madrid, 28033, Spain

  • MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department

    Kryviy Rih, Dnipropetrovsk Oblast, 50048, Ukraine

  • MILAB s.r.o.

    Prešov, 08001, Slovakia

  • MRI SMDLOD "Mediscan" Ltd

    Stara Zagora, 6003, Bulgaria

  • MRRC n.a. A.F. Tsyb - branch of FSBI "NMRC of Radiology" Minzdrav Russia

    Obninsk, Kaluga Oblast, 249036, Russia

  • Maidstone and Tunbridge Wells NHS Trust

    Maidstone, KENT, ME16 9QQ, United Kingdom

  • McGill University Health Center

    Montreal, Quebec, H4A 3J1, Canada

  • Meander Medisch Centrum

    Amersfoort, Utrecht, 3813 TZ, Netherlands

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • Medanta- The Medicity hospital

    Gurugram, Haryana, 122001, India

  • Medical & diagnostic center of LISOD-Israeli Oncological Hosp "MedX-ray International Group"

    Pliuty Village, Kyiv Oblast, 08720, Ukraine

  • Mid-Illinois Hematology & Oncology Associates, Ltd

    Normal, Illinois, 61761, United States

  • Multiprofile Hospital for Active Treatment - Uni Hospital OOD

    Panagyurishte, 4500, Bulgaria

  • Municipal Ent "Dnipropetrovsk Regional Clinical Hosp (I.I.Mechnikov Dnipropetrovsk Regional council)

    Dnipro, 49005, Ukraine

  • Municipal Non-Commercial Enterprise of Kharkiv Regional Council Regional Medical Clinical Center of

    Kharkiv, 61037, Ukraine

  • Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council

    Dnipro, 49102, Ukraine

  • NHS Greater Glasgow and Clyde

    Glasgow, G12 0YN, United Kingdom

  • NHS Lothian

    Edinburgh, Midlothian, EH4 2XU, United Kingdom

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560, Japan

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510515, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, 226000, China

  • Narodny onkologicky ustav

    Bratislava, 833 10, Slovakia

  • National Cancer Center

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • National Cancer Institute

    Kyiv, Kyivska Oblast, 03022, Ukraine

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • National Hospital Organization Hokkaido Cancer Center

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Kumamoto Medical Center

    Kumamoto, 860-0008, Japan

  • National Hospital Organization Kure Medical Center and Chugoku Cancer Center

    Kure, Hiroshima, 737-0023, Japan

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Fukuoka, 811-1395, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, 791-0280, Japan

  • National Hospital Organization Tokyo Medical Center

    Meguro-Ku, Tokyo, 152-8902, Japan

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • Netaji Subhas Chandra Bose Cancer Hospital

    Kolkata, West Bengal, 700094, India

  • New Jersey Cancer Care, P.A.

    Belleville, New Jersey, 07109, United States

  • Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica

    Carrollton, Georgia, 30117, United States

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

    Austell, Georgia, 30106, United States

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

    Cartersville, Georgia, 30121, United States

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

    Douglasville, Georgia, 30134, United States

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia, 30060, United States

  • Oaxaca Site Management Organization

    Oaxaca City, Oaxaca, 68000, Mexico

  • Oncologia Integral Satelite SA de CV

    Naucalpan, State of Mexico, 53100, Mexico

  • Oncology Consultants P.A.

    Houston, Texas, 77030, United States

  • Oncology Consultants, P.A.

    Houston, Texas, 77008, United States

  • Onze Lieve Vrouw Ziekenhuis Aalst

    Aalst, 9300, Belgium

  • Organisation Lawson Health Research Institute

    London, Ontario, N6C2R5, Canada

  • Országos Onkológiai Intézet

    Budapest, 1122, Hungary

  • Osaka International Cancer Institute

    Osaka, Osaka, 5418567, Japan

  • Ospedale San Donato

    Arezzo, 52100, Italy

  • Ospedale Santa Chiara

    Trento, TN, 38122, Italy

  • POKO Poprad s.r.o.

    Poprad, 058 01, Slovakia

  • Parkway Surgery Center

    Myrtle Beach, South Carolina, 29572, United States

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Premier Medical Group of the Hudson Valley PC

    Poughkeepsie, New York, 12603, United States

  • Preparaciones Oncológicas S.C.

    León, Guanajuato, 37178, Mexico

  • Private Institution Educational Organization of Higher Education "Medical University "REAVIZ"

    Samara, 443011, Russia

  • Private Medical Institution "Euromedservice"

    Pushkin, Sankt-Peterburg, 196603, Russia

  • Privatna urologicka ambulancia, s.r.o.

    Trenčín, 911 01, Slovakia

  • Prostate Cancer Centre

    Calgary, Alberta, T2V 1P9, Canada

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon, 97213, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Péterfy Kórház-Rendelőintézet és Manninger Jenő Országos Traumatológiai Intézet

    Budapest, 1076, Hungary

  • Rajiv Gandhi Cancer Institute and Research Centre

    New Delhi, National Capital Territory of Delhi, 110085, India

  • Regional Budgetary Healthcare Institution "Ivanovskiy Regional Oncology Dispensary" (RBHI "IvROD")

    Ivanovo, 153040, Russia

  • Revive Research Institute, Inc.

    Farmington Hills, Michigan, 48334, United States

  • Royal Devon and Exeter NHS Foundation Trust

    Exeter, Devon, EX2 5DW, United Kingdom

  • SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan

    Ufa, 450054, Russia

  • SBIH "Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine"

    Chelyabinsk, 454087, Russia

  • Sahyadri Clinical Research & Development Centre

    Pune, Maharashtra, 411004, India

  • Sahyadri Hospitals Private Limited

    Pune, Maharashtra, 411038, India

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, 411004, India

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Sandton Oncology Medical Group (Pty) Ltd

    Johannesburg, Gauteng, 2196, South Africa

  • Seoul National University Bundang Hospital

    Seongnam, Kyǒnggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, South Yorkshire, S10 2SJ, United Kingdom

  • State Budgetary Institution of Healthcare of Yaroslavl Region "Regional Clinical Oncology Hospital"

    Yaroslavl, 150054, Russia

  • Stichting HagaZiekenhuis

    The Hague, 2545 AA, Netherlands

  • Studienpraxis Urologie

    Nürtingen, 72622, Germany

  • Sykehuset Innlandet Gjoevik

    Gjøvik, 2819, Norway

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tampere University Hospital

    Tampere, 33520, Finland

  • Texas Oncology-Deke Slayton Cancer Center

    Webster, Texas, 77598, United States

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    Seoul, 06591, South Korea

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital Chongqing Medical University

    Chongqing, 400042, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230022, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510230, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, 510120, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061, China

  • The First hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Ottawa Hospital Cancer Center

    Ottawa, Ontario, K1H 8L6, Canada

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, 5011, Australia

  • The Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215004, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, 300211, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, 410013, China

  • The University of Osaka Hospital

    Suita, Osaka, 565-0871, Japan

  • The first affiliated hospital of Ningbo university

    Ningbo, Zhejiang, 315010, China

  • Tokushima University Hospital

    Tokushima, 770-8503, Japan

  • Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

  • Trakya University Medical Faculty

    Edirne, 22030, Turkey (Türkiye)

  • Turku University Hospital

    Turku, 20520, Finland

  • UMHAT "Prof. Dr. Stoyan Kirkovich"

    Stara Zagora, 6003, Bulgaria

  • UROEXAM, spol. s r.o.

    Nitra, 949 01, Slovakia

  • Union Hospital, Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, 430022, China

  • Universitaetsklinik Heidelberg

    Heidelberg, 69120, Germany

  • Universitaetsklinikum Frankfurt

    Frankfurt, 60590, Germany

  • Universitaetsklinikum Tuebingen

    Tübingen, 72076, Germany

  • Universitaetsmedizin Goettingen

    Göttingen, Lower Saxony, 37075, Germany

  • University Health Network-Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B9 5SS, United Kingdom

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • Universitätsklinikum Jena

    Jena, Thuringia, 07747, Germany

  • Uro-/Onkologisches Zentrum

    Leipzig, 04105, Germany

  • Urologicum Duisburg

    Duisburg, 47169, Germany

  • Urologische Gemeinschaftspraxis Wesel

    Wesel, North Rhine-Westphalia, 46483, Germany

  • Urology San Antonio

    San Antonio, Texas, 78229, United States

  • Urology South Shore Research

    Greenfield Park, Quebec, J4V 2H3, Canada

  • Uzsoki Utcai Korhaz

    Budapest, 1145, Hungary

  • VA Long Beach Healthcare System

    Long Beach, California, 90822, United States

  • Valentis Cancer Hospital

    Meerut, Uttar Pradesh, 250001, India

  • Vychodoslovensky onkologicky ustav, a.s.

    Košice, 041 91, Slovakia

  • WCR Office

    Johannesburg, Gauteng, 2193, South Africa

  • Washington Cancer Institute at MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

  • Wellstar Cobb Hospital

    Austell, Georgia, 30106, United States

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

  • West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica

    Carrollton, Georgia, 30117, United States

  • Western Health, Sunshine Hospital

    St Albans, Victoria, 3021, Australia

  • Wits Clinical Research

    Parktown, Gauteng, 2193, South Africa

  • Yale-New Haven Hospital

    New Haven, Connecticut, 06510, United States

  • Yamagata University Hospital

    Yamagata, 990-9585, Japan

  • Yokohama City University Medical Center

    Yokohama, Kanagawa, 232-0024, Japan

  • Yokosukakyosai

    Yokosuka, Kanagawa, 238-8558, Japan

  • ZNA Jan Palfijn

    Merksem, 2170, Belgium

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310014, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009, China

  • oncology Consultants, P.A.

    Houston, Texas, 77024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.